Fintel reports that on August 14, 2023, TD Cowen initiated coverage of Sana Biotechnology (NASDAQ:SANA) with a Market Perform recommendation.
Analyst Price Forecast Suggests 86.81% Upside
As of August 2, 2023, the average one-year price target for Sana Biotechnology is 10.20. The forecasts range from a low of 6.06 to a high of $13.65. The average price target represents an increase of 86.81% from its latest reported closing price of 5.46.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Sana Biotechnology is 0MM. The projected annual non-GAAP EPS is -2.49.
What is the Fund Sentiment?
There are 290 funds or institutions reporting positions in Sana Biotechnology. This is a decrease of 2 owner(s) or 0.68% in the last quarter. Average portfolio weight of all funds dedicated to SANA is 0.05%, a decrease of 13.55%. Total shares owned by institutions increased in the last three months by 7.09% to 142,379K shares. 
The put/call ratio of SANA is 0.10, indicating a bullish outlook.
What are Other Shareholders Doing?
Flagship Pioneering holds 34,239K shares representing 17.39% ownership of the company. No change in the last quarter.
Baillie Gifford holds 10,836K shares representing 5.50% ownership of the company. In it's prior filing, the firm reported owning 10,877K shares, representing a decrease of 0.38%. The firm decreased its portfolio allocation in SANA by 35.29% over the last quarter.
Canada Pension Plan Investment Board holds 10,175K shares representing 5.17% ownership of the company. No change in the last quarter.
Public Sector Pension Investment Board holds 5,371K shares representing 2.73% ownership of the company. In it's prior filing, the firm reported owning 6,400K shares, representing a decrease of 19.15%. The firm increased its portfolio allocation in SANA by 45.32% over the last quarter.
Price T Rowe Associates holds 5,123K shares representing 2.60% ownership of the company. In it's prior filing, the firm reported owning 4,511K shares, representing an increase of 11.96%. The firm decreased its portfolio allocation in SANA by 15.05% over the last quarter.
Sana Biotechnology Background Information
(This description is provided by the company.)
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. Sana shares a vision of repairing and controlling genes, replacing missing or damaged cells, and making its therapies broadly available to patients. Sana is more than 250 people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, and South San Francisco.
Additional reading:
- Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year Expect data later this year from investi
- This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this p
- Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates IND cleared and enrolling patients in SC291 Phase 1 clinical trial in B-cell malignancies with initial data expected later this year SC291 granted Fast Track Designa
- Amendment No. 3 to Option and License Agreement by and between the Company and Beam Therapeutics Inc., dated as of March 17, 2023.
- Offer Letter by and between the Company and Douglas E. Williams, dated as of April 8, 2023.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
